Citations

Clear

4610 citation(s) found for "Lu, Brian".

Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation
Hillman, Shauna L., Mandrekar, Sumithra J. , Bot, Brian M. , DeMatteo, Ronald P. , Perez, Edith A. , Nelson, Heidi , Buckner, Jan C. , Sargent, Daniel J. , Ballman, Karla V. , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | May 18, 2010 | Volume: 28 | Issue: 18 | Pages: 3002-3007

10.1200/jco.2009.27.4282 | PMID 20479400 Get It

Purpose In March 1998, Common Toxicity Criteria (CTC) version 2.0 introduced the collection of attribution of adverse events (AEs) to study drug. We investigate whether attribution adds value to the interpretation of AE data. Patients and Methods Patients in the placebo arm of two phase III trials—North Central Cancer Treatment Group Trial 97-24-51 (carboxyamino-triazole v placebo in advanced non–small-cell lung cancer) and American College of Surgeons Oncology Group Trial Z9001 (imatinib mesylate v placebo after resection of primary gastrointestinal stromal tumors)—were studied. Attribution was categorized as unrelated (not related or unlikely) and related (possible, probable, or definite). Results In total, 398 patients (84 from Trial 97-24-51 and 314 from Trial Z9001) and 7,736 AEs were included; 47% and 50% of the placebo-arm AEs, respectively, were reported as related. When the same AE was reported in the same patient on multiple visits, the attribution category changed at least once 36% and 31% of the time. AE type and sex (Trial Z9001) and AE type and performance status (Trial 97-24-51) were associated with a higher likelihood of AEs being deemed related. Conclusion Nearly 50% of AEs were reported as attributed to study drug on the placebo arm of two randomized clinical trials. These data provide strong evidence that AE attribution is difficult to determine, unreliable, and of questionable value in interpreting AE data in randomized clinical trials.
A window of opportunity for no treatment in early multiple sclerosis?
Gilmore, CP, Cottrell, DA, Scolding, Neil , Wingerchuk, D. M., Weinshenker, B. G., Boggild, M., Weinshenker, Brian G. , Cottrell, David A., Weinshenker, Brian G

Mayo Clinic

Multiple Sclerosis Journal | April 28, 2010 | Volume: 16 | Issue: 6 | Pages: 756-759

10.1177/1352458510366014 | PMID 20427417 Get It

Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained
Ireland, Joanna, Swaidani, Shadi , Li, Geqiang , Bunting, Kevin D. , Finke, James H., Cohen, Peter A. , Ko, Jennifer S. , Rayman, Patricia A. , Rini, Brian I.

Mayo Clinic

Cancer Research | April 20, 2010 | Volume: 70 | Issue: 9 | Pages: 3526-3536

10.1158/0008-5472.can-09-3278 | PMID 20406969 Get It

Abstract The antiangiogenic drug sunitinib is a receptor tyrosine kinase inhibitor with significant, yet not curative, therapeutic effects in metastatic renal cell carcinoma (RCC). Sunitinib is also an immunomodulator, potently reversing myeloid-derived suppressor cell (MDSC) accumulation and T-cell inhibition in the blood even of nonresponder RCC patients. We observed that sunitinib similarly prevented MDSC accumulation and restored normal T-cell function to the spleens of tumor-bearing mice, independent of the capacity of sunitinib to inhibit tumor progression (RENCA>CT26>4T1). Both monocytic and neutrophilic splenic MDSC were highly repressible by sunitinib. In contrast, MDSC within the microenvironment of 4T1 tumors or human RCC tumors proved highly resistant to sunitinib and ambient T-cell function remained suppressed. Proteomic analyses comparing tumor to peripheral compartments showed that granulocyte macrophage colony-stimulating factor (GM-CSF) predicted sunitinib resistance and recombinant GM-CSF conferred sunitinib resistance to MDSC in vivo and in vitro. MDSC conditioning with GM-CSF uniquely inhibited signal transducers and activators of transcription (STAT3) and promoted STAT5 activation. STAT5ab(null/null) MDSC were rendered sensitive to sunitinib in the presence of GM-CSF in vitro. We conclude that compartment-dependent GM-CSF exposure in resistant tumors may account for the regionalized effect of sunitinib upon host MDSC modulation and hypothesize that ancillary strategies to decrease such regionalized escape will enhance the potency of sunitinib as an immunomodulator and a cancer therapy. Cancer Res; 70(9); 3526–36. ©2010 AACR.
A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly
Ho, April J., Stein, Jason L. , Hua, Xue , Lee, Suh , Hibar, Derrek P., Leow, Alex , Dinov, Ivo D. , Toga, Arthur W. , Saykin, Andrew J. , Shen, Li , Pankratz, Nathan , Huentelman, Matthew J. , Craig, David W. , Gerber, Jill D., Allen, April N., Corneveaux, Jason J., Stephan, Dietrich A. , DeCarli, Charles , Dechairo, Bryan, Jack, Clifford R. , Weiner, Michael W. , Raji, Cyrus A. , Becker, James T. , Carmichael, Owen , Thompson, Paul M. , Initiative, the Alzheimer's Disease Neuroimaging, Thal, Leon J., Petersen, Ronald C., Jagust, William J. , Trojanowki, John Q., Toga, Arthur W., Gamst, Anthony, Potter, William Z., Montine, Tom, Anders, Dale, Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene E. , Bandy, Dan, Foster, Norm, Reiman, Eric M. , Shaw, Les, Korecka, Magdalena , Toga, Arthur W., Crawford, Karen , Neu, Scott, Kornak, John , Kachaturian, Zaven, Frank, Richard , Molchan, Susan, Vorobik, Remi, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan , Fleisher, Adam , Vanderswag, Helen, Heidebrink, Judith L. , Johnson, Kris , Doody, Rachelle S., Villanueva‐Meyer, Javier , Chowdhury, Munir , Bell, Karen L. , Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Badger, Beverly, Grossman, Hillel, deToledo‐Morrell, Leyla, Bach, Julie , Duara, Ranjan , Isaacson, Richard , Strauman, Silvia, Albert, Marilyn S. , Pedroso, Julia, Toroney, Jaimie, Santi, Susan M De, Doraiswamy, P. Murali , Petrella, Jeffrey R. , Aiello, Marilyn, Clark, Christopher M. , Pham, Cassie, Nuñez, Jessica, Smith, Charles D., Given, Curtis A., Hardy, Peter , DeKosky, Steven T. , Oakley, MaryAnn, Simpson, Donna M., Ismail, M. Saleem , McCallum, Colleen, Cramer, Steven C. , Mulnard, Ruth A., Mc-Adams-Ortiz, Catherine, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Laubinger, Mary M., Bartzokis, George, Lu, Po H. , Fletcher, Rita, Parfitt, Francine, Farlow, Martin R. , Herring, Scott, Hake, Ann Marie , Dyck, Christopher H. van , MacAvoy, Martha G., Bifano, Laurel A., Chertkow, Howard, Bergman, Howard , Hosein, Chris, Graham, Simon J. , Caldwell, Curtis, Assaly, Michele, Hsiung, Ging‐Yuek Robin , Kertesz, Andrew , Trost, Dick, Bernick, Charles , Johnson, Nancy , Sadowsky, Carl, Villena, Teresa, Mesner, Scott, Aisen, Paul, Johnson, Kathleen, Behan, Kelly E., Johnson, Keith A. , Rosen, Allyson , Tinklenberg, Jared, Ashford, Wes, Connor, Donald J., Obradov, Sanja, Jayam‐Trouth, Annapurni , Wang, Paul J. , Auchus, Alexander P. , Huang, Juebin , DeCarli, Charles , Kittur, Smita, Mirje, Seema, Borrie, Michael, Lee, T‐Y, Asthana, Sanjay , Carlsson, Cynthia M., Highum, Diane, Preda, Adrian , Tariot, Pierre N. , Hendin, Barry , Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Gandy, Sam, Marenberg, Marjorie E., Rovner, Barry W. , Blank, Karen, Anderson, Karen, Santulli, Robert B. , Paré, Nadia, Williamson, Jeff D. , Raj, Balebail Ashok, Giordano, Amy T., Ott, Brian R. , Wu, Chuang‐Kuo, Cohen, Ronald A. , Wilks, Kerri, Lee, Ting‐Yim , Foroud, Tatiana , Potkin, Steven G. , López, Oscar L. , Initiative, the Alzheimer's Disease Neuroimaging, Toga, Arthur W., Beckett, Laurel , Green, Robert C. , Bernstein, Matt A. , Fox, Nick C. , Koeppe, Robert A. , Foster, Norm, Chen, Kewei , Lee, Virginia M.‐Y. , Toga, Arthur W., Harvey, Danielle , Snyder, Peter J. , Kaye, Jeffrey , Quinn, Joseph F. , Lord, Joanne L. , Stern, Yaakov , Honig, Lawrence S. , Morris, John C. , Tang, Cheuk Ying , Stern, Jessica A. , Shah, Raj C. , Duara, Ranjan , Rusinek, Henry , Leon, Mony J. de , Porsteinsson, Anton P. , Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Black, Sandra E. , Feldman, Howard , ROGERS, John H. , Gitelman, Darren R. , Mesulam, Marsel M. , Sperling, Reisa Anne , Rentz, Dorene M. , Sabbagh, Marwan Noel , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Friedland, Robert P. , Fletcher, Evan M. , Johnson, Sterling C. , Nguyen, Dana R. , Scharre, Douglas W. , Beversdorf, David Q. , Gandy, Sam , Pearlson, Godfrey D. , Sink, Kaycee M. , Potter, Huntington , Jack, Clifford R , Saykin, Andrew J , Shen, Li , Preda, Adrian , Toga, Arthur W , Stein, Jason L , Thompson, Paul M , Hsiung, Gink-Yuek , Pankratz, Nathan

Mayo Clinic

Proceedings of the National Academy of Sciences | April 19, 2010 | Volume: 107 | Issue: 18 | Pages: 8404-8409

10.1073/pnas.0910878107 | PMID 20404173 Get It

A recently identified variant within the fat mass and obesity-associated ( FTO ) gene is carried by 46% of Western Europeans and is associated with an ~1.2 kg higher weight, on average, in adults and an ~1 cm greater waist circumference. With >1 billion overweight and 300 million obese persons worldwide, it is crucial to understand the implications of carrying this very common allele for the health of our aging population. FTO is highly expressed in the brain and elevated body mass index (BMI) is associated with brain atrophy, but it is unknown how the obesity-associated risk allele affects human brain structure. We therefore generated 3D maps of regional brain volume differences in 206 healthy elderly subjects scanned with MRI and genotyped as part of the Alzheimer's Disease Neuroimaging Initiative. We found a pattern of systematic brain volume deficits in carriers of the obesity-associated risk allele versus noncarriers. Relative to structure volumes in the mean template, FTO risk allele carriers versus noncarriers had an average brain volume difference of ~8% in the frontal lobes and 12% in the occipital lobes—these regions also showed significant volume deficits in subjects with higher BMI. These brain differences were not attributable to differences in cholesterol levels, hypertension, or the volume of white matter hyperintensities; which were not detectably higher in FTO risk allele carriers versus noncarriers. These brain maps reveal that a commonly carried susceptibility allele for obesity is associated with structural brain atrophy, with implications for the health of the elderly.
Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration
Stambolian, Dwight, Edwards, Albert O., Branham, Kari , Othman, Mohammad , Jakobsdóttir, Jóhanna , Tosakulwong, Nirubol , Pericak‐Vance, Margaret A. , Klein, Michael L. , Tan, Perciliz L. , Kanda, Atsuhiro , Kopplin, Laura J. , Li, Yanming , Augustaitis, Katherine J., Karoukis, Athanasios J., Scott, William K. , Agarwal, Anita , Kovach, Jaclyn L. , Postel, Eric A. , Brooks, Matthew, Baratz, Keith H. , Brown, William L. , Brucker, Alexander J., Orlin, Anton, Brown, Gary C. , Ho, Allen C. , Regillo, Carl D. , Donoso, Larry A., Tian, Lifeng , Kaderli, Brian, Hadley, Dexter , Hagstrom, Stephanie A. , Peachey, Neal S. , Klein, Ronald , Klein, Barbara E.K. , Gotoh, Norimoto, Yamashiro, Kenji , Ferris, Frederick L. , Fagerness, Jesen, Reynolds, Robyn, Farrer, Lindsay A. , Kim, Ivana K. , Miller, Joan W. , Cortón, Marta , Carracedo, Ángel , Sánchez‐Salorio, Manuel, Pugh, Elizabeth, Doheny, Kimberly F. , Brión, Marı́a , Weeks, Daniel E. , Zack, Donald J. , Heckenlively, John R., Yoshimura, Nagahisa , Iyengar, Sudha K. , Francis, Peter J. , Katsanis, Nicholas , Seddon, Johanna M. , Haines, Jonathan L. , Abecasis, Gonçalo R. , Swaroop, Anand , Johnson, Robert N., Ai, Everett, McDonald, H. Richard , Stolarczuk, Margaret, Pavan, Peter R., Billiris, Karina K., Iyer, Mohan , Menosky, Matthew M., Pautler, Scott E. , Millard, Sharon M., Hubbard, G. Baker , Aaberg, Thomas , DuBois, Lindy, Lyon, Alice T., Anderson-Nelson, Susan, Jampol, Lee M. , Muñana, Annie, Rozenbajgier, Zuzanna, Orth, David H., Cohen, Jack, MacCumber, Matthew, Figliulo, Celeste, Porcz, Liz, Folk, James C. , Boldt, H. Culver , Russell, Stephen R. , Ivins, Rachel, Hinz, Connie J., Bloom, Steve, Jaegers, Ken, Kritchman, Brian, Whittington, Greg K., Frederick, Albert R., Morley, Michael G., Topping, Trexler M., Davis, Heather L., Bressler, Susan B., Bressler, Neil M. , Doll, W T Jr, Trese, Michael T. , Garretson, Bruce R., Ruby, Alan, Osentoski, Tammy, Ruszczyk, Margaret, Grand, G., Joseph, Daniel P., Shah, Gaurav K. , Nobel, Ginny, Antoszyk, Andrew N., Stallings, Alison H, Singerman, Lawrence J. , Miller, David T. , Novák, Michael, Pendergast, Scott, Zegarra, Hernando, Schura, Stephanie A., Smith-Brewer, Sheila, Davidorf, Frederick H., Chorich, Louis J., Salerno, Jill, Dreyer, Richard F., Ma, Colin, Kopfer, Marcia, Wilson, David J. , Nolte, Susan K., Grunwald, Juan E. , Dunaief, Josh, Fine, Stuart L., Maguire, Albert M. , Stoltz, Robert A., McRay, Monique, Fish, Gary E., Anand, Rajiv, Spencer, Rand , Arnwine, Jean, Chandra, Suresh R., Blodi, Barbara, Gottlieb, Justin L., Ip, Michael S. , Nork, T. Michael , Perry-Raymond, Jennie, Brightwell-Arnold, Mary, Harkins, Sandra, Peskin, Ellen, Ying, Gui‐Shuang , Kurinij, Natalie, Chen, Wei , Campochiaro, Peter A. , Conley, Yvette P. , Schwartz, Stephen G. , DeAngelis, Margaret M. , Chew, Emily Y. , Gorin, Michael B. , Menosky, Matthew M., Weinberg, David V. , Barr, Charles C. , Heier, Jeffrey S. , Capone, A. , Hassan, T. , McCannel, Colin A. , Blinder, Kevin J. , Holekamp, Nancy M. , Browning, David J. , Chambers, Robert , Altaweel, Michael M. , Maguire, Maureen G. , Weeks, Daniel E , Brion, María , Abecasis, Gonçalo

Mayo Clinic

Proceedings of the National Academy of Sciences | April 12, 2010 | Volume: 107 | Issue: 16 | Pages: 7401-7406

10.1073/pnas.0912702107 | PMID 20385819 Get It

We executed a genome-wide association scan for age-related macular degeneration (AMD) in 2,157 cases and 1,150 controls. Our results validate AMD susceptibility loci near CFH ( P < 10 −75 ), ARMS2 ( P < 10 −59 ), C2/CFB ( P < 10 −20 ), C3 ( P < 10 −9 ), and CFI ( P < 10 −6 ). We compared our top findings with the Tufts/Massachusetts General Hospital genome-wide association study of advanced AMD (821 cases, 1,709 controls) and genotyped 30 promising markers in additional individuals (up to 7,749 cases and 4,625 controls). With these data, we identified a susceptibility locus near TIMP3 (overall P = 1.1 × 10 −11 ), a metalloproteinase involved in degradation of the extracellular matrix and previously implicated in early-onset maculopathy. In addition, our data revealed strong association signals with alleles at two loci ( LIPC , P = 1.3 × 10 −7 ; CETP , P = 7.4 × 10 −7 ) that were previously associated with high-density lipoprotein cholesterol (HDL-c) levels in blood. Consistent with the hypothesis that HDL metabolism is associated with AMD pathogenesis, we also observed association with AMD of HDL-c—associated alleles near LPL ( P = 3.0 × 10 −3 ) and ABCA1 ( P = 5.6 × 10 −4 ). Multilocus analysis including all susceptibility loci showed that 329 of 331 individuals (99%) with the highest-risk genotypes were cases, and 85% of these had advanced AMD. Our studies extend the catalog of AMD associated loci, help identify individuals at high risk of disease, and provide clues about underlying cellular pathways that should eventually lead to new therapies.
EUDOC on the IBM Blue Gene/L system: Accelerating the transfer of drug discoveries from laboratory to patient
Pang, Yuan‐Ping , Mullins, Tim, Swartz, Brent, McAllister, J. S., Smith, Brian E., Archer, Charles J, Musselman, Roy, Peters, Amanda, Wallenfelt, Brian, Pinnow, K. W., Pang, Yuan-Ping

Mayo Clinic

IBM Journal of Research and Development | April 5, 2010 | Volume: 52 | Issue: 1.2 | Pages: 69-81

10.1147/rd.521.0069 Get It

Properties of WT and mutant hERG K+ channels expressed in neonatal mouse cardiomyocytes
Holzem, Katherine M., Anson, Blake D., Moungey, Brooke M. , Balijepalli, Sadguna Y., Tester, David J. , Ackerman, Michael J. , Delisle, Brian P. , Balijepalli, Ravi C. , January, Craig T., Lin, Eric C.

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | April 5, 2010 | Volume: 298 | Issue: 6 | Pages: H1842-H1849

10.1152/ajpheart.01236.2009 | PMID 20363883 Get It

Mutations in human ether-a-go-go-related gene 1 ( hERG) are linked to long QT syndrome type 2 (LQT2). hERG encodes the pore-forming α-subunits that coassemble to form rapidly activating delayed rectifier K+ current in the heart. LQT2-linked missense mutations have been extensively studied in noncardiac heterologous expression systems, where biogenic (protein trafficking) and biophysical (gating and permeation) abnormalities have been postulated to underlie the loss-of-function phenotype associated with LQT2 channels. Little is known about the properties of LQT2-linked hERG channel proteins in native cardiomyocyte systems. In this study, we expressed wild-type (WT) hERG and three LQT2-linked mutations in neonatal mouse cardiomyocytes and studied their electrophysiological and biochemical properties. Compared with WT hERG channels, the LQT2 missense mutations G601S and N470D hERG exhibited altered protein trafficking and underwent pharmacological correction, and N470D hERG channels gated at more negative voltages. The ΔY475 hERG deletion mutation trafficked similar to WT hERG channels, gated at more negative voltages, and had rapid deactivation kinetics, and these properties were confirmed in both neonatal mouse cardiomyocyte and human embryonic kidney (HEK)-293 cell expression systems. Differences between the cardiomyocytes and HEK-293 cell expression systems were that hERG current densities were reduced 10-fold and deactivation kinetics were accelerated 1.5- to 2-fold in neonatal mouse cardiomyocytes. An important finding of this work is that pharmacological correction of trafficking-deficient LQT2 mutations, as a potential innovative approach to therapy, is possible in native cardiac tissue.
Optimal Allocation of Surgery Blocks to Operating Rooms Under Uncertainty
Miller, Andrew J. , Balasubramanian, Hari , Huschka, Todd R., Denton, Brian T.

Mayo Clinic

Operations Research | March 25, 2010 | Volume: 58 | Issue: 4-part-1 | Pages: 802-816

10.1287/opre.1090.0791 Get It

The allocation of surgeries to operating rooms (ORs) is a challenging combinatorial optimization problem. There is also significant uncertainty in the duration of surgical procedures, which further complicates assignment decisions. In this paper, we present stochastic optimization models for the assignment of surgeries to ORs on a given day of surgery. The objective includes a fixed cost of opening ORs and a variable cost of overtime relative to a fixed length-of-day. We describe two types of models. The first is a two-stage stochastic linear program with binary decisions in the first stage and simple recourse in the second stage. The second is its robust counterpart, in which the objective is to minimize the maximum cost associated with an uncertainty set for surgery durations. We describe the mathematical models, bounds on the optimal solution, and solution methodologies, including an easy-to-implement heuristic. Numerical experiments based on real data from a large health-care provider are used to contrast the results for the two models and illustrate the potential for impact in practice. Based on our numerical experimentation, we find that a fast and easy-to-implement heuristic works fairly well, on average, across many instances. We also find that the robust method performs approximately as well as the heuristic, is much faster than solving the stochastic recourse model, and has the benefit of limiting the worst-case outcome of the recourse problem.
Clostridium septicumAortitis and Cecal Adenocarcinoma
Moseley, Brian D. , Mwirigi, Nicola W., Bowen, J R

Mayo Clinic

Case Reports in Medicine | March 7, 2010 | Volume: 2010 | Issue: No issue available | Pages: 1-3

10.1155/2010/121728 | PMID 20224641 Get It

Clostridium septicumaortitis is a rare infection that is highly associated with underlying malignancy. We present a case of an 82-year-old male diagnosed with bothC. septicumaortitis and a high-grade cecal tubulovillous adenoma. The patient was offered aortic resection; however, he opted for only suppressive antibiotic therapy and a right hemicolectomy with ileocolonic anastomosis. He ultimately passed away 75 days following admission. The authors report on the connection betweenC. septicumaortitis and malignancy. The authors also discuss the need for prompt treatment with antibiotics once the infection is identified and the consideration of aortic resection given the risk of aneurysmal change with aortic dissection or rupture.
Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma
Crowley, John, Bladé, Joan , Miguel, Jesús F. San , Kyle, Robert A. , Rajkumar, S. Vincent , Shimizu, Kazuyuki , Turesson, Ingemar , Westin, Jan, Sonneveld, Pieter , Cavo, Michèle , Boccadoro, Mario , Palumbo, Antonio , Harousseau, Jean‐Luc, Barlogie, Bart , Stewart, A. Keith , Durie, Brian G.M. , Ludwig, Heinz , Bolejack, Vanessa , Tosi, Patrizia , Attal, Michel , Rajkumar, S Vincent , San-Miguel, Jesus

Mayo Clinic

Journal of Clinical Oncology | February 23, 2010 | Volume: 28 | Issue: 9 | Pages: 1599-1605

10.1200/jco.2009.25.2114 | PMID 20177027 Get It

Purpose To assess the impact of age on outcome and to analyze the projected years of life lost in patients with multiple myeloma. Patients and Methods Ten thousand five hundred forty-nine patients were evaluated; 6,996 patients were treated with conventional chemotherapy, and 3,553 patients were treated with high-dose therapy with autologous stem-cell transplantation. Results Mean observed and relative overall survival times in the entire cohort were 3.7 and 3.9 years, respectively. Observed survival decreased steadily from 6.4 years in patients younger than age 50 years to 2.5 years in patients ≥ age 80 years. A similar decrease was noted for relative survival. Higher age correlated significantly with higher International Staging System (ISS) stage. Relative excess risk of death differed significantly between 10-year age cohorts beginning from age 40 years (P < .001 for age 50 to 59 v age 40 to 49, P < .001 for age 60 to 69 v age 50 to 59, P < .001 for age 70 to 79 v age 60 to 69, and P = .009 for age ≥ 80 v 70 to 79). The average years of life lost per patient was 16.8 years in the entire patient cohort and decreased steadily from 36.1 years in patients younger than 40 years old to 4.6 years in patients ≥ age 80 years. Conclusion Age is associated with higher ISS stage and is an important risk factor for early mortality. Survival declined continuously by each decade from age 50 to age ≥ 80 from more than 6 to less than 3 years. The average of years of life lost in patients with myeloma is higher than in many other cancers and amounts to more than 30 years in patients younger than 40 years old but decreases to less than 5 years in patients age 80 years or older.